N- (3- (2- dimethylaminoethyl)- 1H- indol- 5- yl)- 5- chloronaphthalene- 2- sulfonamide

5-HT(6) receptor ligand and an antiobesity agent; structure in first source

Also Known As:

5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulphonamide; E-6837; N-DAEI-5-chloro-NS

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - N-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-5-chloronaphthalene-2-sulfonamide: 1
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-5-chloronaphthalene-2-sulfonamide: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-5-chloronaphthalene-2-sulfonamide: 1

Experts

1.	Buschmann, Helmut: 1 article (08/2006)
2.	Codony, Xavier: 1 article (08/2006)
3.	Dordal, Alberto: 1 article (08/2006)
4.	Fisas, Angels: 1 article (08/2006)
5.	Giraldo, Jesus: 1 article (08/2006)
6.	Heal, David: 1 article (08/2006)
7.	Holenz, Jörg: 1 article (08/2006)
8.	Mercé, Ramon: 1 article (08/2006)
9.	Pauwels, Petrus Johan: 1 article (08/2006)
10.	Romero, Gonzalo: 1 article (08/2006)

Related Diseases

1.	Weight Gain 08/01/2006 - "Although weight regain occurred after withdrawal from either compound, the body weights after E-6837 (-6.6%) remained lower than after sibutramine (-3.8%) indicating that the greater efficacy of the former did not result in profound rebound hyperphagia/weight gain. "
2.	Hyperphagia (Overeating) 08/01/2006 - "Although weight regain occurred after withdrawal from either compound, the body weights after E-6837 (-6.6%) remained lower than after sibutramine (-3.8%) indicating that the greater efficacy of the former did not result in profound rebound hyperphagia/weight gain. "
3.	Body Weight (Weight, Body) 08/01/2006 - "Sustained body weight loss and decreased cumulative food intake of DIO-rats was observed with E-6837 (30 mg kg(-1), p.o., twice a day) during the 4-week treatment period. " 08/01/2006 - " effects of chronic treatment with E-6837 were determined in diet-induced obese (DIO)-rats on changes in body weight, food and water intake, plasma indices of comorbid risk factors, and weight regain on compound withdrawal. " 08/01/2006 - "Although weight regain occurred after withdrawal from either compound, the body weights after E-6837 (-6.6%) remained lower than after sibutramine (-3.8%) indicating that the greater efficacy of the former did not result in profound rebound hyperphagia/weight gain. " 08/01/2006 - "The onset of the E-6837 effect on body weight was slower than that of sibutramine (5 mg kg(-1), p.o.), while its maximal effect was greater, that is -15.7 versus -11.0%.E-6837-induced weight loss was exclusively mediated by a decrease (31.7%) in fat mass, with a concomitant reduction (49.6%) in plasma leptin. "
4.	Weight Loss (Weight Reduction) 08/01/2006 - "Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats." 08/01/2006 - "These results show that the 5-HT(6) receptor partial agonist, E-6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine." 08/01/2006 - "The onset of the E-6837 effect on body weight was slower than that of sibutramine (5 mg kg(-1), p.o.), while its maximal effect was greater, that is -15.7 versus -11.0%.E-6837-induced weight loss was exclusively mediated by a decrease (31.7%) in fat mass, with a concomitant reduction (49.6%) in plasma leptin. "
5.	Obesity 08/01/2006 - "These results show that the 5-HT(6) receptor partial agonist, E-6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine."

Related Drugs and Biologics

1.	sibutramine (Meridia)
2.	Leptin
3.	serotonin 6 receptor